Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2023)
24 slides from Patrys's shareholder meeting presentation, Nov 15, 2023
Slide 1: Chair's Address and CEO Presentation at Annual General Meeting
ASX & Media Release Chair’s Address and CEO Presentation at Annual General Meeting Melbourne, Australia; 15 November 2023: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to release the Chair’s Address and Chief Executive Officer (CEO) Pre
Slide 2: Chair's Address (continued)
run that was to produce drug material for our Phase 1 clinical trial was most likely a random, and sporadic event. As you will recall, this process was used without any issues in 2022 to make material for our toxicology studies. We have been working tirelessly to ensure that when we recommence manuf
Slide 3: Concluding Remarks
Concluding Remarks: Despite the challenges that the past Financial Year presented, Patrys’ team has worked tirelessly to advance its deoxymab programs, and, where required, to identify and rectify problems as they have arisen. The Company remains focused on getting its deoxymabs into the clinic and
Slide 4: About Patrys' deoxymab 3E10 platform
About Patrys’ deoxymab 3E10 platform: Patrys’ deoxymab platform is based on the deoxymab 3E10 antibody that was first identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). While most antibodies bind to cell surface markers, deoxymab 3E10 penetrates i
Slide 5: CEO Presentation November 2023
For personal use only 2023 AGM Presentation Dr James Campbell CEO and MD 15 November 2023
Slide 6: Safe harbour statement
Safe harbour statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 7: Investment summary
Investment summary For personal use only Patrys’ deoxymab technology platform provides new ways for using antibodies to treat cancer: • Block repair of damaged DNA • Cross the blood brain barrier • Can be used alone or in combination with other therapies Deoxymab antibodies can be used as targeting
Slide 8: Company snapshot
Company snapshot For personal use only 12 month share price performance Shares 2.1B Market cap¹ A$20.6M Cash² A$5.3M HQ Melbourne Charmaine Gittleson (Chair) Board James Campbell (CEO & MD) Pamela Klein (NED) Mike Stork (NED) Price¹ $0.010 Substantial Dr Dax Marcus Calder – 11.2% 12 mth high - low $
Slide 9: Board of Directors
Board of Directors For personal use only Dr Charmaine Gittleson Dr Pamela M. Klein • Former Chief Medical Officer of CSL Limited • Former VP, Development at Genentech • Global expertise in drug development, • Board member of Argenx (Euronext & Nasdaq: ARGX) clinical development, regulatory strategy
Slide 10: FY23 Highlights – PAT-DX1
FY23 Highlights – PAT-DX1 ✓ Jul 2022 – PAT-DX1 engineering run successfully completed For personal use only ✓ Aug 2022 – PAT-DX1 engineering run material meets specifications ✓ Apr 2023 – PAT-DX1/radiation combo improves brain cancer survival ✓ May 2023 – Favourable initial GLP tox reports for PAT-D
Slide 11: FY23 Highlights - other
FY23 Highlights - other For personal use only ✓ Aug 2022 – Research grant investigating use of deoxymabs for breast cancer ✓ Oct 2022 – PAT-DX3 crosses blood brain barrier in healthy animals ✓ Nov 2023 – Dr Charmaine Gittleson appointed Chairman ✓ Mar 2023 – New data showing PAT-DX3 demonstrates syn
Slide 12: Antibody manufacturing is complex and expensive
Antibody manufacturing is complex and expensive AUDIT CONFIRMED COMPLIANCE WITH GMP For personal use only PROCESS CONTAMINANT NO CONTAMINANTS FOUND IDENTIFIED DURING IN MASTER CELL BANK PROUCTION RUN Master Cell Media Bank storage preparation Large Chromatography bioreactor Small Chromatography Prod
Slide 13: Technology Overview
For personal use only Overview Technology
Slide 14: Deoxymabs: multiple therapeutic approaches
Deoxymabs: multiple therapeutic approaches For personal use only Single Agent Combination Therapies Targeted Therapies • Active against cancers that have • Radiation therapy and many chemo • Deoxymabs can be used to defects in their DNA damage repair drugs work by causing damage to DNA target delive
Slide 15: PAT-DX1 – anticancer activity in multiple models
PAT-DX1 – anticancer activity in multiple models For personal use only As a single agent • 47% improvement in survival in an animal model of glioblastoma Mice with high-grade glioma • Most common primary brain cancer (23,000 new cases in US pa) In combination with radiation • 25% improvement in surv
Slide 16: Commercial Landscape
For personal use only Landscape Commercial
Slide 17: Deal landscape - recent examples
Deal landscape - recent examples For personal use only October 28, 2022 • Merck KGaA (Xetra, €20B) acquired the ex-China rights to a novel PARP inhibitor and a novel ADC developed by Jiangsu Hengrui Pharmaceuticals (Shanghai, $314M) • €160M up front, total potential value € 1.56B • PARP inhibitor, H
Slide 18: Deal landscape - recent examples
Deal landscape - recent examples For personal use only November 1, 2022 • Exelixis (NASDAQ, US$5.3B) and Cybrexa Therapeutics (US, private) establish exclusive collaboration giving Exelixis the Right to Acquire CBX- 12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan • US$60 million up
Slide 19: Looking Ahead
For personal use only Ahead Looking
Slide 20: PAT-DX1 clinical trial preparation for H2 CY 2024
PAT-DX1 clinical trial preparation for H2 CY 2024 For personal use only • Cell line for manufacturing selected in 2021 and engineering run successfully completed in July 2022 • GMP run failed in Q1 CY 2023, being rescheduled • No major concerns identified in either non-GLP or GLP toxicology studies
Slide 21: PAT-DX3 development path
PAT-DX3 development path For personal use only • PAT-DX3 is differentiated from PAT-DX1 o Different pharmacokinetic profile o Crosses the blood brain barrier independent of cancer in the brain o Efficacy in animal models • Potential for use as a targeting agent (more conjugation sites than PAT-DX1)
Slide 22: The year ahead
The year ahead For personal use only PAT-DX1 GMP production run complete Q1 2024 PAT-DX1 Human Research Ethics Application submission Q3 2024 PAT-DX1 phase 1 clinical study initiation H2 2024 PAT-DX3 nucleic acid payload collaborations Ongoing Platform expansion Ongoing Patents and publications Ongo
Slide 23: The Patrys value proposition
The Patrys value proposition For personal use only Patrys’ deoxymab antibodies have a novel target and mechanism, and are effective in animal models of multiple cancer types Deoxymabs target indications with significant unmet medical need – including triple negative breast cancer, primary and second
Slide 24: Contact
Contact For personal use only Dr. James Campbell CEO and MD +61 3 9670 3273 info@patrys.com patrys.com Patrys Limited (ASX:PAB)